Greenphire has announced an expansion of its agreement with Merck, known as MSD outside the US and Canada. This expanded agreement now includes the use of Greenphire's ClinCard with rideshare integration for participants across Merck's clinical development network.
Greenphire's ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on participants. ClinCard does not impose costs on sites and helps ensure patients are reimbursed in a timely manner so research sites can focus on conducting clinical trials.
Greenphire Expands Agreement with Merck to Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide. (2023, March 13). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.